With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the latest installment of BioWorld’s series on the BCI field, Rotem Kopel, CEO of Ability Neurotech SA, explains that following in the footsteps of the established players has its advantages. “It's not too bad to be a fast follower to a company like Neuralink.” Ability and its peers are either building more complete systems, or exploring different approaches from electrodes with newer materials to nanoparticles, while addressing technical and clinical challenges identified by earlier entrants and targeting different indications.

Cortec GmbH is preparing to implant its brain-computer interface (BCI) technology into a third stroke patient, with early clinical data showing that the device leads to significant improvement in hand and arm function. The company believes its Brain Interchange system could transform the lives of millions of patients.

As the development of brain-computer interface (BCI) technologies gain momentum, Paradromics Inc. is building an ecosystem to enable collaboration between the company and academic researchers.

Neurosoft Bioelectronics SA has signed an agreement with Science Corp. to gain access to its full stack of clinical-grade neural recording tools as it looks to advance its brain-computer interface (BCI) system.

Inbrain Neuroelectronics SL closed a $50 million series B financing round to advance clinical trials for its graphene-based brain-computer interface therapeutics platform. The company also secured additional funding from Merck KGaA GmbH which will go towards developing the technology for application across both central and peripheral nervous systems.